These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22292446)

  • 1. Drug treatment of obesity in cardiovascular disease.
    Charakida M; Finer N
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):93-104. PubMed ID: 22292446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity: new perspectives and pharmacotherapies.
    Palamara KL; Mogul HR; Peterson SJ; Frishman WH
    Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medications for weight reduction.
    Bray GA
    Endocrinol Metab Clin North Am; 2008 Dec; 37(4):923-42. PubMed ID: 19026940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
    Hemo B; Endevelt R; Porath A; Stampfer MJ; Shai I
    Diabetes Res Clin Pract; 2011 Nov; 94(2):269-75. PubMed ID: 21907442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug therapy for obesity.
    Dickerson LM; Carek PJ
    Am Fam Physician; 2000 Apr; 61(7):2131-8, 2143. PubMed ID: 10779254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options.
    Fujioka K
    Obes Res; 2002 Dec; 10 Suppl 2():116S-123S. PubMed ID: 12490660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do we need anti-obesity drugs?
    Hainer V; Hainerová IA
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():8-20. PubMed ID: 23280861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.
    Czernichow S; Lee CM; Barzi F; Greenfield JR; Baur LA; Chalmers J; Woodward M; Huxley RR
    Obes Rev; 2010 Feb; 11(2):150-8. PubMed ID: 19573052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why do we need drugs to treat the patient with obesity?
    Bray GA
    Obesity (Silver Spring); 2013 May; 21(5):893-9. PubMed ID: 23520198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-obesity drugs: a review about their effects and their safety.
    Derosa G; Maffioli P
    Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent concepts of pharmacotherapy and bariatric surgery for childhood obesity: an overview.
    Gogakos A; Tzotzas TC; Krassas GE
    Pediatr Endocrinol Rev; 2009 Dec; 7(2):3-14. PubMed ID: 20118889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
    Lee M; Aronne LJ
    Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A practicing physician's view on obesity].
    Juhász A; Katona E; Csongrádi E; Paragh G
    Orv Hetil; 2006 Apr; 147(13):579-90. PubMed ID: 16623440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-being of obese individuals: therapeutic perspectives.
    Chaput JP; Tremblay A
    Future Med Chem; 2010 Dec; 2(12):1729-33. PubMed ID: 21428796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.